Granules India Next On PE Buy List?
EIR Obtained For Chantilly, US Facility
A recent focus on high-margin generic formulations, strong contract manufacturing business, and expected cash inflow from stake sales in joint ventures could make Granules India an attractive buy for PE funds.
You may also be interested in...
With a majority stake in Bharat Serums, Advent gains access to biologics in gynecology and high-potential assisted reproductive technology. The deal also provides an exit to two other PE funds - OrbiMed and Kotak.
Granules India has ambitions to become a vertically integrated player in cancer therapies after the company ended joint ventures for contract research and manufacturing services as well as for making bulk ibuprofen.
Vildagliptin formulation prices fall by over 70% following the expiry of a patent held by Novartis in India. The innovator, meanwhile, is cashing in on co-marketing agreements with Indian partners like USV and Cipla